TrialAnnals of the rheumatic diseases2012

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

Jeffrey Kaine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.